Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network
Guo Lin1,2, Zhuoran Yao1,2, Kai Kang1,2
1Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Background:
The efficacy and toxicity profiles for extensive-stage small cell lung cancer (ES-SCLC) are unclear. We aimed to address this gap through a Bayesian network meta-analysis.
Methods:
We performed network analysis from randomized controlled trials comparing these treatments: PD-(L)1 inhibitor, CTLA-4 inhibitor, CXCR inhibitor, PARP inhibitor, CDK inhibitor, chemotherapy, and their combinations. Pooled estimations of progression-free survival, overall survival, objective response rate, and toxicity (systematic and specific) were conducted within the Bayesian framework.
Results:
Twenty-five trials involving 9 strategies were included. In terms of progression-free survival and overall survival, PD-(L)1 inhibitor combined with cisplatin/carboplatin (P) and etoposide (E) shown the acknowledged superiority than other treatments. The addition of CTLA-4 inhibitor (ipilimumab) to EP had the highest response rate among these regimens, and the combination of chemotherapy (irinotecan) and cisplatin/carboplatin had the greatest probability of performing considerable systematic security. The secondary endpoint was specific adverse events, including vomiting, fatigue, thrombocytopenia, constipation, and decreased appetite; hence we depicted the specific toxicity profile of each regimen. In addition, we identified the differences between PD-1 inhibitors and PD-L1 inhibitors in prolonging overall survival time for the central nervous system (CNS)/liver metastases patients.
Conclusions:
EP combined with PD-(L)1 inhibitor followed by CTLA-4 inhibitors or anti-angiogenesis was the considerable treatment with considerable efficacy and safety for ES-SCLC. Each treatment has a unique specific toxicity profile, which needs more attention.
Insights
The best treatment for extensive-stage small cell lung cancer (ES-SCLC) is PD-(L)1 inhibitors with chemotherapy (etoposide/cisplatin). This combination offers superior survival and response rates, though specific toxicities require attention.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Efficacy and toxicity of treatments for extensive-stage small cell lung cancer (ES-SCLC) remain unclear.
- A Bayesian network meta-analysis was conducted to address this knowledge gap.
Purpose of the Study:
- To compare the efficacy and toxicity of various treatment strategies for ES-SCLC.
- To identify optimal treatment regimens based on progression-free survival, overall survival, and response rates.
Main Methods:
- Network meta-analysis of randomized controlled trials comparing PD-(L)1 inhibitors, CTLA-4 inhibitors, chemotherapy, and combinations.
- Pooled estimations of progression-free survival, overall survival, objective response rate, and toxicity were performed.
Main Results:
- PD-(L)1 inhibitor combined with etoposide/cisplatin (EP) demonstrated superior progression-free and overall survival.
- Adding a CTLA-4 inhibitor (ipilimumab) to EP yielded the highest response rate.
- Chemotherapy (irinotecan) with cisplatin/carboplatin showed the best safety profile regarding systematic toxicity.
Conclusions:
- EP combined with PD-(L)1 inhibitors is a highly effective and safe treatment for ES-SCLC.
- Individual treatment regimens possess distinct toxicity profiles that warrant careful consideration.
More Related Videos
Related Concept Videos
01:21Cancer Survival Analysis
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...